Epinephrine is the only effective treatment for serious allergic reactions called anaphylaxis, yet people with prescriptions for the lifesaving medication often don t carry their auto-injectors, and many hesitate to use them.
Share this article
Share this article
RALEIGH, N.C., Feb. 27, 2021 /PRNewswire/ Bryn Pharma, LLC ( Bryn or the Company ), a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced positive clinical results from its multi-dose study of BRYN-NDS1C (bi-dose epinephrine nasal spray). Results from the study demonstrated that administration of epinephrine with one spray/dosing from Bryn s two-dose nasal spray device resulted in a favorable release profile with both short- and long-term pharmacokinetic (PK) outcomes that were comparable to or greater than those seen with administration by a single 0.3 mg epinephrine auto-injector. No safety issues were seen and there were no serious or unexpected adverse events with either intranasal (IN) or intramuscular (IM) dosing.